Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Invested Capital (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Invested Capital for 6 consecutive years, with $308.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital rose 22.76% to $308.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $308.2 million, a 22.76% increase, with the full-year FY2025 number at $308.2 million, up 22.76% from a year prior.
  • Invested Capital was $308.2 million for Q4 2025 at GeneDx Holdings, down from $347.1 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $648.3 million in Q2 2022 to a low of -$565.2 million in Q2 2021.
  • A 5-year average of $249.6 million and a median of $305.3 million in 2023 define the central range for Invested Capital.
  • Biggest YoY gain for Invested Capital was 296.71% in 2021; the steepest drop was 282.55% in 2021.
  • GeneDx Holdings' Invested Capital stood at $399.1 million in 2021, then crashed by 34.85% to $260.0 million in 2022, then dropped by 9.88% to $234.3 million in 2023, then grew by 7.14% to $251.0 million in 2024, then rose by 22.76% to $308.2 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Invested Capital are $308.2 million (Q4 2025), $347.1 million (Q3 2025), and $332.3 million (Q2 2025).